Dermata Therapeutics, Inc. (DRMA): Nasdaq/NYSE listing notice — Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity

Dermata Therapeutics, Inc.

Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.
Company reported stockholders' equity of $1.6M as of Dec 31, 2024, below required threshold.
Dermata has 45 days, until May 9, 2025, to submit a plan; possible extension to Sept 21, 2025.
Securities continue trading on Nasdaq while company evaluates options to regain compliance.
If plan rejected or compliance not regained, delisting proceedings may commence; hearing available.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 25, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Capital Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company reported stockholders’ equity of approximately $1.6 million, which is below the required minimum.

View on SEC.gov

Browse all listing & compliance notices →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-25-003305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.